Vizora日本語

SymBio PharmaceuticalsSymBio Pharmaceuticals Limited4582東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

SymBio Pharmaceuticals FY ending Dec 2021 results

SymBio Pharmaceuticals brought in ¥8.26B in revenue.

Out of every ¥100 of sales, about ¥12 is left as operating profit.

Revenue changed +176.4% from the prior year, and it swung back to an operating profit.

Revenue and profit pattern

Turned profitable

What changed from last year

FY ending Dec 2020 → FY ending Dec 2021

Revenue
+176.4%¥2.99B → ¥8.26B
Gross profit
+569.6%¥866.9M → ¥5.8B
Operating income
Back to profit-¥4.51B → ¥1.02B
Operating cash flow
Back to profit-¥4.12B → ¥140M
Free cash flow
Back to profit-¥4.27B → ¥76.2M

Where the money goes

FY ending Dec 2020 → FY ending Dec 2021

Where ¥100 of sales goes

For every ¥100 SymBio Pharmaceuticals sells, how much goes where, and how much is kept.

FY ending Dec 2021
Cost of sales
¥30
SG&A
¥58
Operating profit
¥12
Net profit kept
¥25

Annual margin trends

Gross margin70.3%
FY ending Dec 2019: 30.5%30.5%FY ending Dec 2020: 29.0%29.0%FY ending Dec 2021: 70.3%70.3%FY19FY20FY21
Operating margin12.3%
FY ending Dec 2019: -151.6%-151.6%FY ending Dec 2020: -150.9%-150.9%FY ending Dec 2021: 12.3%12.3%FY19FY20FY21
Net margin24.6%
FY ending Dec 2019: -154.2%-154.2%FY ending Dec 2020: -136.9%-136.9%FY ending Dec 2021: 24.6%24.6%FY19FY20FY21

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (2)

  • EDINET (FSA Japan)

    有価証券報告書－第17期(令和3年1月1日－令和3年12月31日)

    ID S100NPZC2022-03-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第16期(令和2年1月1日－令和2年12月31日)

    ID S100L0KX2021-03-24Open

Extracted from XBRL: 43 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image